The US Food and Drug Administration approves Cobenfy (KarXT), the first new agent with a novel mechanism of action for schizophrenia more than 50 years.
News
Mental health clinicians can help empower patients via tools like diet, including the MIND Diet.
This book seeks to reduce the stigma surrounding teen pregnancy.
Enter your email to see the results of our polls on social media usage amongst mental health clinicians!
Psychiatrists and mental health clinicians: a social determinant of health.
Celebrating 4 years of Psychiatry & Society!
Are there parts of the movie “It Ends With Us” that could have suicide protective effects for viewers?
New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.
Learn more about the latest viral substance abuse trend.
Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.
Reports of suicidality with GLP-1RA antiobesity medication are supported by analysis of WHO data, but no association is found in large population cohort study or analysis of clinical trials.
A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.
Saturday was the International Day of Peace.
Rural areas suffer from a severe shortage of mental health professionals. How can nurse practitioners help?
How comfortable do you feel in your knowledge of this type of treatment?
Enter your email to check out this complicated case!
Later this month, the FDA will vote on KarXT, a novel muscarinic acetylcholine receptor agonist.
Here’s what Dr Moffic plans to cover in this week…
Why are experts excited about KarXT, a novel muscarinic acetylcholine receptor agonist that, if approved, is poised to revolutionize schizophrenia treatment?
A therapist asks a question that makes me glimpse the eternal.
In this CME article, learn how best to provide end-of-life care to patients with psychiatric disorders.
John Krystal, MD, explores the future of ketamine and psychedelics in psychiatry, shedding light on their potential to improve patient care by increasing options treatment options.
The context and timing of symptoms is critical for a timely and accurate bipolar diagnosis.
"One September morning, the day I started medical school, I placed a two-foot specimen in my sunny south window."
Are we reliving the evolution of managed care from the 1980s and 1990s?
Meeting the needs of the dying and their families requires a deep and clear understanding of competent and compassionate care.
Is the complex posttraumatic stress disorder diagnosis being used to avoid the diagnosis of borderline personality disorder?
How can we improve rural mental health?
Advertisement
Advertisement